CAS No.:183133-96-2

Cabazitaxel (CAS No.: 183133-96-2), a semi-synthetic taxane derivative, is a pivotal microtubule inhibitor approved for metastatic castration-resistant prostate cancer (mCRPC) treatment. Marketed as Jevtana®, it binds to β-tubulin subunits, stabilizing microtubules and arresting cells in the G2/M p…